Status:
COMPLETED
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
Lead Sponsor:
Pfizer
Conditions:
SARS-CoV-2
COVID-19
Eligibility:
All Genders
6-4 years
Brief Summary
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
Eligibility Criteria
Inclusion
- Children aged 6 months to 4 years at the time of the booster vaccination (4th dose) who (or whose representative) gave written consent to take part in the study.
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
March 6 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 26 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06130410
Start Date
March 6 2024
End Date
July 26 2024
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Local Country
Tokyo, Japan, 1518589